PortalPublikationenConditioning-based outcomes after allogeneic transplantation...

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

Standard

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. / Hayden, Patrick J; Iacobelli, Simona; Pérez-Simón, José Antonio; van Biezen, Anja; Minnema, Monique; Niittyvuopio, Riitta; Schönland, Stefan; Meijer, Ellen; Blaise, Didier; Milpied, Noel; Márquez-Malaver, Francisco J; Veelken, Joan Hendrik; Maertens, Johan; Michallet, Mauricette; Cammenga, Jörg; N'Guyen, Stephanie; Niederwieser, Dietger; Hunault-Berger, Mathilde; Bourhis, Jean Henri; Passweg, Jakob; Bermudez, Arancha; Chalandon, Yves; Yakoub-Agha, Ibrahim; Garderet, Laurent; Kröger, Nicolaus.

in: EUR J HAEMATOL, Jahrgang 104, Nr. 3, 03.2020, S. 181-189.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hayden, PJ, Iacobelli, S, Pérez-Simón, JA, van Biezen, A, Minnema, M, Niittyvuopio, R, Schönland, S, Meijer, E, Blaise, D, Milpied, N, Márquez-Malaver, FJ, Veelken, JH, Maertens, J, Michallet, M, Cammenga, J, N'Guyen, S, Niederwieser, D, Hunault-Berger, M, Bourhis, JH, Passweg, J, Bermudez, A, Chalandon, Y, Yakoub-Agha, I, Garderet, L & Kröger, N 2020, 'Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP', EUR J HAEMATOL, Jg. 104, Nr. 3, S. 181-189. https://doi.org/10.1111/ejh.13352

APA

Hayden, P. J., Iacobelli, S., Pérez-Simón, J. A., van Biezen, A., Minnema, M., Niittyvuopio, R., Schönland, S., Meijer, E., Blaise, D., Milpied, N., Márquez-Malaver, F. J., Veelken, J. H., Maertens, J., Michallet, M., Cammenga, J., N'Guyen, S., Niederwieser, D., Hunault-Berger, M., Bourhis, J. H., ... Kröger, N. (2020). Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. EUR J HAEMATOL, 104(3), 181-189. https://doi.org/10.1111/ejh.13352

Vancouver

Hayden PJ, Iacobelli S, Pérez-Simón JA, van Biezen A, Minnema M, Niittyvuopio R et al. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. EUR J HAEMATOL. 2020 Mär;104(3):181-189. https://doi.org/10.1111/ejh.13352

Bibtex

@article{574d4bc0b899475f8fa77f3d74c1dade,
title = "Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP",
abstract = "OBJECTIVES: The aim of this study was to compare the effect of the intensity of conditioning approaches used in allogeneic transplantation in myeloma-reduced intensity conditioning (RIC), non-myeloablative (NMA), myeloablative conditioning (MAC) or Auto-AlloHCT-on outcomes in patients who had had a prior autologous transplant.METHODS: A retrospective analysis of the EBMT database (1991-2012) was performed.RESULTS: A total of 344 patients aged between 40 and 60 years at the time of alloHCT were identified: 169 RIC, 69 NMA, 65 MAC and 41 Auto-Allo transplants. At a median follow-up of 54 months, the probabilities of overall survival (OS) at 5 years were 39% (95% CI 31%-47%), 45% (95% CI 32%-57%), 19% (95% CI 6%-32%) and 34% (95% CI 17%-51%), respectively. Status at allogeneic HCT other than CR or PR conferred a 70% higher risk of death and a 40% higher risk of relapse. OS was markedly lower in the MAC group (P = .004). MAC alloHCT was associated with a higher risk of death than RIC alloHCT until 2002 (HR = 4.1, P < .001) but not after 2002 (HR = 1.2, P = .276).CONCLUSION: From 1991 to 2002, MAC was associated with poorer OS. Between 2003 and 2012, there were no significant differences in outcomes based on these different approaches.",
author = "Hayden, {Patrick J} and Simona Iacobelli and P{\'e}rez-Sim{\'o}n, {Jos{\'e} Antonio} and {van Biezen}, Anja and Monique Minnema and Riitta Niittyvuopio and Stefan Sch{\"o}nland and Ellen Meijer and Didier Blaise and Noel Milpied and M{\'a}rquez-Malaver, {Francisco J} and Veelken, {Joan Hendrik} and Johan Maertens and Mauricette Michallet and J{\"o}rg Cammenga and Stephanie N'Guyen and Dietger Niederwieser and Mathilde Hunault-Berger and Bourhis, {Jean Henri} and Jakob Passweg and Arancha Bermudez and Yves Chalandon and Ibrahim Yakoub-Agha and Laurent Garderet and Nicolaus Kr{\"o}ger",
note = "{\textcopyright} 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2020",
month = mar,
doi = "10.1111/ejh.13352",
language = "English",
volume = "104",
pages = "181--189",
journal = "EUR J HAEMATOL",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

AU - Hayden, Patrick J

AU - Iacobelli, Simona

AU - Pérez-Simón, José Antonio

AU - van Biezen, Anja

AU - Minnema, Monique

AU - Niittyvuopio, Riitta

AU - Schönland, Stefan

AU - Meijer, Ellen

AU - Blaise, Didier

AU - Milpied, Noel

AU - Márquez-Malaver, Francisco J

AU - Veelken, Joan Hendrik

AU - Maertens, Johan

AU - Michallet, Mauricette

AU - Cammenga, Jörg

AU - N'Guyen, Stephanie

AU - Niederwieser, Dietger

AU - Hunault-Berger, Mathilde

AU - Bourhis, Jean Henri

AU - Passweg, Jakob

AU - Bermudez, Arancha

AU - Chalandon, Yves

AU - Yakoub-Agha, Ibrahim

AU - Garderet, Laurent

AU - Kröger, Nicolaus

N1 - © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2020/3

Y1 - 2020/3

N2 - OBJECTIVES: The aim of this study was to compare the effect of the intensity of conditioning approaches used in allogeneic transplantation in myeloma-reduced intensity conditioning (RIC), non-myeloablative (NMA), myeloablative conditioning (MAC) or Auto-AlloHCT-on outcomes in patients who had had a prior autologous transplant.METHODS: A retrospective analysis of the EBMT database (1991-2012) was performed.RESULTS: A total of 344 patients aged between 40 and 60 years at the time of alloHCT were identified: 169 RIC, 69 NMA, 65 MAC and 41 Auto-Allo transplants. At a median follow-up of 54 months, the probabilities of overall survival (OS) at 5 years were 39% (95% CI 31%-47%), 45% (95% CI 32%-57%), 19% (95% CI 6%-32%) and 34% (95% CI 17%-51%), respectively. Status at allogeneic HCT other than CR or PR conferred a 70% higher risk of death and a 40% higher risk of relapse. OS was markedly lower in the MAC group (P = .004). MAC alloHCT was associated with a higher risk of death than RIC alloHCT until 2002 (HR = 4.1, P < .001) but not after 2002 (HR = 1.2, P = .276).CONCLUSION: From 1991 to 2002, MAC was associated with poorer OS. Between 2003 and 2012, there were no significant differences in outcomes based on these different approaches.

AB - OBJECTIVES: The aim of this study was to compare the effect of the intensity of conditioning approaches used in allogeneic transplantation in myeloma-reduced intensity conditioning (RIC), non-myeloablative (NMA), myeloablative conditioning (MAC) or Auto-AlloHCT-on outcomes in patients who had had a prior autologous transplant.METHODS: A retrospective analysis of the EBMT database (1991-2012) was performed.RESULTS: A total of 344 patients aged between 40 and 60 years at the time of alloHCT were identified: 169 RIC, 69 NMA, 65 MAC and 41 Auto-Allo transplants. At a median follow-up of 54 months, the probabilities of overall survival (OS) at 5 years were 39% (95% CI 31%-47%), 45% (95% CI 32%-57%), 19% (95% CI 6%-32%) and 34% (95% CI 17%-51%), respectively. Status at allogeneic HCT other than CR or PR conferred a 70% higher risk of death and a 40% higher risk of relapse. OS was markedly lower in the MAC group (P = .004). MAC alloHCT was associated with a higher risk of death than RIC alloHCT until 2002 (HR = 4.1, P < .001) but not after 2002 (HR = 1.2, P = .276).CONCLUSION: From 1991 to 2002, MAC was associated with poorer OS. Between 2003 and 2012, there were no significant differences in outcomes based on these different approaches.

U2 - 10.1111/ejh.13352

DO - 10.1111/ejh.13352

M3 - SCORING: Journal article

C2 - 31737951

VL - 104

SP - 181

EP - 189

JO - EUR J HAEMATOL

JF - EUR J HAEMATOL

SN - 0902-4441

IS - 3

ER -